Peptide-drug Conjugate Information
General Information of This Peptide-drug Conjugate (PDC)
| PDC ID |
PDC_00233
|
|||||
|---|---|---|---|---|---|---|
| PDC Name |
KYL-TGX
|
|||||
| PDC Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Prostate cancer
|
|||||
| Structure |
|
|||||
| Peptide Name |
LNCaP-specific peptide
|
Peptide Info | ||||
| Receptor Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Receptor Info | ||||
| Drug Name |
TGX-D1
|
Drug Info | ||||
| Therapeutic Target |
Phosphatidylinositol 3-kinase catalytic subunit type 3 (PIK3C3)
|
Target Info | ||||
| Linker Name |
PSA-cleavable linker (SSKYQSL)
|
Linker Info | ||||
| Peptide Modified Type |
Amino acid modifications
|
|||||
| Modified Segment |
Modified with acetyl group
|
|||||
| Ternimal Modification |
N-terminal modification
|
|||||
| Formula |
C137H192N32O35
|
|||||
| #Ro5 Violations (Lipinski): 5 | Molecular Weight | 2847.232 | ||||
| Lipid-water partition coefficient (xlogp) | -5.82488 | |||||
| Hydrogen Bond Donor Count (hbonddonor) | 34 | |||||
| Hydrogen Bond Acceptor Count (hbondacc) | 42 | |||||
| Rotatable Bond Count (rotbonds) | 93 | |||||
Full List of Activity Data of This Peptide-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Prostate cancer | ||||
| Efficacy Data | Inhinition rate |
14.93 µM
|
|||
| Administration Time | 72 h | ||||
| In Vitro Model | Prostate carcinoma | LNCaP C4-2 cell | CVCL_4782 | ||
| Half life period | 4 h | ||||
References